Turning attention to Blautix...13 Nov 2020 10:43
This is an extract from the IBS phase 2 results management presentation:
"Edward Thomason, N+1 Singer
Yeah, follow that. And look two more if I may. I just want to understand the intention after this. Whether you talk about plans for Phase II, would that be again across all subtypes or just for IBS-M or and again, just the corporate strategy for Blautix now and whether you will look to do develop this independently or with a partner.
Duncan Peyton, Chief Executive Officer, 4D pharma
That’s a good question, Edward. I think you know we’re still going through the analysis as is, working out what the trial would look like, so it’s still early days in terms of exactly which path we’re going to take. I think, as you know, and I’ll let Glenn come on this, we’ve been talking to a few potential partners as well, so we'll follow all those conversations as well, Glenn?
Glenn Dourado, Chief Business Officer, 4D pharma
Yeah, thanks Duncan. Just to add on that, we have been in constant contact with all the major players in the IBS space as well as other companies that have expressed interest given the stage that the program is at, and so a number of them were waiting for these Phase II results to be released so we'll certainly follow up with them and see where the interest lies but there is definite interest from major players.
Edward Thomason, N+1 Singer
OK, good to hear, when are we probably going to be expecting the data, the full data from the IBS trial then?
Dr Alex Stevenson, Chief Scientific Officer, 4D pharma
So that will be before the end of the year."
Sign In
Follow the stocks
